Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 14,600 shares, a decrease of 67.3% from the February 13th total of 44,700 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 59,100 shares, the days-to-cover ratio is currently 0.2 days.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.
Check Out Our Latest Stock Report on Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Price Performance
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The business had revenue of $6.01 billion for the quarter. As a group, research analysts expect that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.
Fresenius SE & Co. KGaA Company Profile
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Read More
- Five stocks we like better than Fresenius SE & Co. KGaA
- How to Capture the Benefits of Dividend Increases
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Growth Stocks and Investing in Them
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Investing in Commodities: What Are They? How to Invest in Them
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.